Results 111 to 120 of about 5,308 (216)

Real-World Evidence of the Long-Term Effectiveness of 0.2 μg/Day Fluocinolone Acetonide Implant in Persistent and Recurrent Diabetic Macular Edema – A Single Center Study

Clinical Ophthalmology
Ricardo Machado Soares,* Catarina Cunha Ferreira,* Joana da Silva Fernandes, Carolina Madeira, Luís MA Silva, Eduardo Saraiva, Lígia Ribeiro, Sofia Fonseca Department of Ophthalmology - Centro Hospitalar Vila Nova de Gaia e Espinho, Porto ...
Soares RM, Ferreira CC, Fernandes JDS, Madeira C, Silva LMA, Saraiva E, Ribeiro L, Fonseca S   +7 more
doaj  

Post-cataract outcomes in patients with noninfectious posterior uveitis treated with the fluocinolone acetonide intravitreal implant

Clinical Ophthalmology, 2012
John D Sheppard Jr1, Quan Dong Nguyen2, Dale W Usner3, Timothy L Comstock3, for the Fluocinolone Acetonide Uveitis Study Group1Eastern Virginia Medical School, Norfolk, VA, USA; 2Wilmer Ophthalmological Institute, Johns Hopkins University, Baltimore, MD,
Sheppard Jr JD, Nguyen QD, Usner DW, Comstock TL; Fluocinolone Acetonide Uveitis Study Group   +3 more
doaj  

Rapid Structural and Functional Improvements with the 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Patients with DME and Low Visual Acuity: 6-Month Data from the UAE

Clinical Ophthalmology, 2020
Ahmed Mohammed Elbarky1,2 1Vitreoretinal consultant, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates; 2Department of Ophthalmology, Benha Faculty of Medicine, Benha University, Benha, EgyptCorrespondence: Ahmed Mohammed Elbarky Email abarky ...
Elbarky AM
doaj  

Bioavailability and activity of 0.1% amcinonide preparations: comparison with proprietary topical corticosteroid formulations of differing potencies [PDF]

, 1979
The activity of a 0.1% amcinonide cream was compared with those of selected proprietary topical corticosteroid formulations of potencies differing according to the United Kingdom (U.K.) MIMS classification (very potent, potent and moderately potent ...
Haigh, J M, Woodford, R
core   +1 more source

Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME) [PDF]

, 2015

core   +1 more source

Good syndrome and other causes of cytomegalovirus retinitis in HIV-negative patients—case report and comprehensive review of the literature [PDF]

, 2016

core   +1 more source

Long-Term Control of Retinal Thickness Variability and Vision Following the 0.19 mg Fluocinolone Acetonide Implant. [PDF]

J Vitreoretin Dis, 2023
Sheth VS, Singer M, MacCumber M, Cutino A, Kasper J, Coughlin BA, Riemann CD.   +6 more
europepmc   +1 more source

Delayed-Onset Wound Leakage and Endophthalmitis After Intravitreal Implantation of Fluocinolone Acetonide. [PDF]

J Vitreoretin Dis
Chang PS, Yu JH, Chun DW, Ali MH, Levinson JD, Do BK, Melamud A.   +6 more
europepmc   +1 more source

Fluocinolone Acetonide Implant Injected 1 Month after Dexamethasone Implant for Diabetic Macular Oedema: the ILUVI1MOIS Study. [PDF]

Ophthalmol Ther, 2023
Rousseau N, Lebreton O, Masse H, Maucourant Y, Pipelart V, Clement M, Le Lez ML, Khanna RK, Pepin M, Eude Y, Le Meur G, Weber M, Ducloyer JB.   +12 more
europepmc   +1 more source

Fluocinolone acetonide implant in diabetic macular edema: sustained benefits and effects of following prior therapy. [PDF]

Int J Retina Vitreous
Necpal P, Kaiser KP, Kroener RC, Singh P.   +3 more
europepmc   +1 more source